Resistance to fosfomycin is increasing and is significantly associated with extended-spectrum β-lactamase-production in urinary isolates of Escherichia coli
Medical Microbiology and Immunology · 2022-12 · 211 (5-6) · 269-272
DOI: 10.1007/s00430-022-00749-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Microbiology and Immunology, online erschienen am 03.09.2022. Verfasst von Esther Ríos und 4 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Medicina (Microbiología), Facultad de Medicina, Universidad Complutense de Madrid, Pza. Ramón y Cajal, s/n, 28040, Madrid, Spain. eri…. Hauptthemen laut MEDLINE: Fosfomycin, Escherichia coli Infections, Urinary Tract Infections. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidad Complutense de Madrid.
Abstract (Originalsprache)
Fosfomycin has become a therapeutic option in urinary tract infections. Our objective was to evaluate the in vitro activity of fosfomycin against Escherichia coli isolated from urine samples in 2013, 2018 and 2021. We also determined a putative association between fosfomycin resistance and extended-spectrum β-lactamases (ESBL) production. Fosfomycin activity was evaluated against 7367, 8128 and 5072 Escherichia coli urinary isolates in 2013, 2018 and 2021, respectively. We compare the prevalence of fosfomycin-resistant strains among the ESBL- and non-ESBL-producing isolates. MICs of fosfomycin, cefotaxime, and cefotaxime-clavulanate were determined by a microdilution method. 302 ESBL-producers were selected to determine MICs of fosfomycin by agar dilution and genes encoding ESBLs were detected by PCR. Among the total of ESBL-producing strains, 14.3%, 20.8% and 20% were resistant to fosfomycin in 2013, 2018 and 2021, respectively, whereas fosfomycin resistance in non-ESBL producers was 3.5%, 4.05% and 5.53% for each year ( P ≤ 0.001). In the 302 selected ESBL-producing isolates, CTX-M was the main ESBL (228 isolates), being 50.7% CTX-M-15. Resistance to fosfomycin among these ESBL-producing strains was associated ( P = 0.049) with isolates that produced the CTX-M type. Our data show that fosfomycin resistance is increasing in Escherichia coli urinary isolates and it is related to ESBL-production. A follow-up of fosfomycin resistance is required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departamento de Medicina (Microbiología), Facultad de Medicina, Universidad Complutense de Madrid, Pza. Ramón y Cajal, s/n, 28040, Madrid, Spain. erios02@ucm.es.
- Servicio de Microbiología, Hospital Clínico San Carlos, C/ Profesor Martín Lagos, s/n., 28040, Madrid, Spain.
- Departamento de Medicina (Microbiología), Facultad de Medicina, Universidad Complutense de Madrid, Pza. Ramón y Cajal, s/n, 28040, Madrid, Spain.
Förderung
- Universidad Complutense de Madrid
Zitieren
APA
Ríos, E., Del Carmen López Diaz, M., Culebras, E., Rodríguez-Avial, I., & Rodríguez-Avial, C. (2022). Resistance to fosfomycin is increasing and is significantly associated with extended-spectrum β-lactamase-production in urinary isolates of Escherichia coli. Medical Microbiology and Immunology, 211(5-6), 269-272. https://doi.org/10.1007/s00430-022-00749-2
Vancouver
Ríos E, Del Carmen López Diaz M, Culebras E, Rodríguez-Avial I, Rodríguez-Avial C. Resistance to fosfomycin is increasing and is significantly associated with extended-spectrum β-lactamase-production in urinary isolates of Escherichia coli. Medical Microbiology and Immunology. 2022;211(5-6):269-272. doi:10.1007/s00430-022-00749-2
BibTeX
@article{Ros2022,
author = {Ríos, Esther and Del Carmen López Diaz, María and Culebras, Esther and Rodríguez-Avial, Iciar and Rodríguez-Avial, Carmen},
title = {Resistance to fosfomycin is increasing and is significantly associated with extended-spectrum β-lactamase-production in urinary isolates of Escherichia coli},
journal = {Medical Microbiology and Immunology},
year = {2022},
volume = {211},
number = {5-6},
pages = {269--272},
doi = {10.1007/s00430-022-00749-2}
}
EUVIMED